{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:29Z","timestamp":1761513869199},"reference-count":60,"publisher":"Baishideng Publishing Group Inc.","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4254\/wjh.v8.i24.1012","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T10:18:15Z","timestamp":1472120295000},"page":"1012","source":"Crossref","is-referenced-by-count":5,"title":["Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension"],"prefix":"10.4254","volume":"8","author":[{"given":"Alberto","family":"Ferrarese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zanetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Germani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Burra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.023"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.235473"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2003.01804.x"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21907"},{"key":"ref7","unstructured":"Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-894."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.042"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-14-18"},{"key":"ref10","unstructured":"Sagarad SV, Chawla YK, Dhiman RK. Portal hemodynamics after large-volume paracentesis in patients with liver cirrhosis and tense ascites. Dig Dis Sci 1998;43:2470-2472."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(96)70068-9"},{"key":"ref12","unstructured":"Farr M, Schulze PC. Recent advances in the diagnosis and management of cirrhosis-associated cardiomyopathy in liver transplant candidates: advanced echo imaging, cardiac biomarkers, and advanced heart failure therapies. Clin Med Insights Cardiol 2014;8:67-74."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.04.033"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.180570"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-014-3432-8"},{"key":"ref16","unstructured":"Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985;5:97-101."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198112033052302"},{"key":"ref18","unstructured":"Hayes PC, Davis JM, Lewis JA, Bouchier IA. Meta-analysis of value of propranolol in prevention of variceal haemorrhage. Lancet 1990;336:153-156."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.05.022"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004544.pub2"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2013.805811"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23775"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23881"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23852"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24176"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.01.034"},{"key":"ref27","unstructured":"Llach J, Ginès P, Arroyo V, Rimola A, Titó L, Badalamenti S, Jiménez W, Gaya J, Rivera F, Rodés J. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28264"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04308.x"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306502"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.948053"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30087-8"},{"key":"ref33","unstructured":"Pereira GH, Baldin C, Victor L, Piedade J, Guimar\u00e3es L, Rocha T, Pereira L. Use of non-selective beta blockers (nsbb) in cirrhotic patients with bacterial infections is associated with lower frequency of sepsis, but not of acute-on-chronic liver failure (ACLF) or survival. Results of a prospective study. J Hepatol 2016;64:S263."},{"key":"ref34","unstructured":"Mallawaarachchi N, Sinha R, Hayes P. Does the use of non-selective beta-blockers in cirrhosis patients with ascites result in increased mortality? J Hepatol 2016;64:S278-279."},{"key":"ref35","unstructured":"Bhutta AQ, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary JG, Bajaj J. Beta-blocker use in hospitalized cirrhotic patients with ascites is associated with a lower MELD, less inflammation and an improved survival. J Hepatol 2016;64:S245."},{"key":"ref36","unstructured":"Onali S, Kalafateli M, Majumdar A, Westbrook M, O’Beirne J, Patch D, Tsochatzis E Non-selective beta blockers (NSBBS) use is associated with improved survival in cirrhotic patients with ascites: a single centre retrospective study.  J Hepatol 2016;64:S668."},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.018"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50447"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.005"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24053"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.01.072"},{"key":"ref42","unstructured":"Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996;25:909-915."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.12.003"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36947"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12634"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.10.028"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50133"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.456"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.014"},{"key":"ref50","unstructured":"Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186-193."},{"key":"ref51","unstructured":"Pérez-Paramo M, Mu\u00f1oz J, Albillos A, Freile I, Portero F, Santos M, Ortiz-Berrocal J. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000;31:43-48."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(11)60612-0"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.12.011"},{"key":"ref54","unstructured":"Cholongitas E, Papatheodoridis GV, Manesis EK, Burroughs AK, Archimandritis AJ. Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? J Gastroenterol Hepatol 2006;21:581-587."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02038.x"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.028"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.043"},{"key":"ref58","unstructured":"Thorhauge KH, Lindvig KP, Laleman W, Angeli P, Singh SP, Krag A. Lack of consensus for usage of β-blockers in end-stage liver disease. Gut 2016;65:1058-1060."},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301348"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26676"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i24\/1012.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T01:23:33Z","timestamp":1509672213000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v8\/i24\/1012.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":60,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v8.i24.1012","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}